Factors that Affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-Interventional, Retrospective Cohort Study

Önder, Çağatay Emir; Kuşkonmaz, Şerife Mehlika; Fırat, Sevde Nur; Omma, Tülay; Taşkaldıran, Işılay; Gokbulut, P; Culha, Cavit

doi:10.4183/aeb.2020.443

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study enrolled more patients, and included a longer follow-up time than previous real-world studies in Turkey ( 21 , 22 ). However, some key limitations should be considered when interpreting our study’s results.…”

Section: Discussionmentioning

confidence: 99%

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

Öner¹,

Gunhan²,

Yavuz³

2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

AimTo evaluate the effects of insulin degludec/insulin aspart (IDegAsp) coformulation as an intensification of insulin treatment for glycemic control in patients with type 2 diabetes (T2D) in a long term real-world clinical setting.Materials and MethodsThis retrospective non-interventional study, included 210 patients with T2D who to IDegAsp coformulation from prior insulin treatment in a tertiary endocrinology center between September 2017 and December 2019. The baseline data was taken as the index date and defined as the first IDegAsp prescription claim. Previous insulin treatment modalities, hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight were recorded, respectively at the 3rd, 6th, 12th, and 24th months of the IDegAsp treatment.ResultsOut of the total 210 patients, 166 patients under insulin treatment switched to twice-daily IDegAsp treatment, 35 patients switched to once daily IDegAsp and twice premeal short-acting insulin regimen as a modified basal-bolus (BB) treatment, and nine patients commenced with once-daily IDegAsp treatment. HbA1c decreased from 9.2% ± 1.9% to 8.2% ± 1.6% in 6 months, 8.2% ± 1.7% in the first year, and 8.1% ± 1.6% in the second year of the therapy (p< 0.001). FPG decreased from 209.0 ± 85.0 mg/dL to 147.0 ± 62.6 mg/dL in the second year (p< 0.001). The required total daily dose of insulin increased in the second year of IDegAsp treatment compared to baseline. However, there was a borderline significance increase in IDegAsp requirement for the whole group at the two-year follow-up (p = 0.05). Patients who were administered twice daily IDegAsp injections required more total insulin in the first and second years due to added premeal short-acting insulin injections (p < 0.05). The frequency of patients with HbA1c < 7% was 31.8% in first year and 35.8% in second year under IDegAsp treatment.Insulin dose was de-escalated in 28.5% of the patients under BB treatment, while 15% under twice-daily IDegAsp required increased BB treatment.ConclusionIntensification of insulin treatment with IDegAsp coformulation improved glycemic control in patients with T2D. The total daily insulin requirement increased but the IDegAsp requirement lightly increased at the two-year follow-up. Patients under BB treatment required de-escalation of insulin treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

Öner¹,

Gunhan²,

Yavuz³

2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

show abstract

Evaluation of the efficiency of insulin degludec/insulin aspart therapy in controlling hyperglycemia and hypoglycemia in patients with type 2 diabetes mellitus: a real-life experience

Semiz

Selimoğlu

Arayıcı

et al. 2022

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy

Altay

Farzaliyeva

İyidir

et al. 2023

EMIDDT

View full text Add to dashboard Cite

Aim: A co-formulation containing insulin degludec and insulin aspart (IDegAsp) is available for the treatment of diabetes in Turkey. We aimed to evaluate the clinical results of switching to IDegAsp treatment for Type 2 diabetes. Method: A total of 217 patients with type 2 diabetes treated with IDegAsp and having follow-up data were included. The patients were divided into 3 groups. Group 1 switched from basal insulin to IDegAsp, group 2 switched from twice-daily premixed insulin regimen to IdegAsp, and group 3 switched from intensive and thrice-daily premixed insulin regimen to IDegAsp. Groups were evaluated in terms of changes in insulin dose, the number of injections, and changes in HbA1c. Results: The mean follow-up period was 7.5±4.4 months. The mean age was 62.8±12.9 years. The mean duration of diabetes was 15.3±8 years. There was a significant decrease in HbA1c and glucose (p<0.0001 and p<0.0001, respectively). HbA1c was significantly reduced in group 1 (p<0.0001) while insulin dose and the number of injections increased (p<0.0001 and p<0.0001, respectively). HbA1c, insulin dose, and the number of injections in group 2 and group 3 (p=0.001, p=0.002, p<0.0001, respectively, and p<0.0001, p=0.043, p<0.0001, respectively) were significantly reduced. method: A total of 217 patients with type 2 diabetes treated with IDegAsp and have follow-up data were included. The patients were divided into 3 groups. Group 1 is switched from basal insulin to IDegAsp, group 2 is switched from twice daily premixed insulin regimen to IDegAsp and group 3 is switched from intensive and thrice daily premixed insulin regimen to IDegAsp. Groups were evaluated in terms of changes in insulin dose, the number of injections, and changes in HbA1c. Conclusion: This study includes real-life experiences involving a remarkable number of patients in the literature. IDegAsp treatment provided effective blood glucose regulation and caused a significant decrease in the insulin dose and the number of injections, resulting in increased quality of life among those who had to receive twice or more insulin injections.

show abstract

Factors that Affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-Interventional, Retrospective Cohort Study

Cited by 3 publications

References 16 publications

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

Evaluation of the efficiency of insulin degludec/insulin aspart therapy in controlling hyperglycemia and hypoglycemia in patients with type 2 diabetes mellitus: a real-life experience

The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy

Contact Info

Product

Resources

About